Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10881971 | 0.84 | KDM4E (0.44) | KDM4EALDH1A1HSD17B10ACP3NR4A1 | |
| SCHEMBL4678773 | 0.83 | KDM4E (0.53) | KDM4EALDH1A1HSD17B10ACP3NR4A1 | |
| SCHEMBL7287554 | 0.83 | KDM4E (0.53) | KDM4EALDH1A1HSD17B10ACP3NR4A1 | |
| SCHEMBL4592424 | 0.83 | KDM4E (0.53) | KDM4EALDH1A1HSD17B10ACP3NR4A1 | |
| SCHEMBL10412004 | 0.81 | ALDH1A1 (0.44) | KDM4EALDH1A1HSD17B10ACP3CYP2C19 | |
| SCHEMBL8563130 | 0.81 | ALDH1A1 (0.44) | KDM4EALDH1A1HSD17B10ACP3CYP2C19 | |
| SCHEMBL11106851 | 0.80 | PDK1 (0.50) | KDM4EALDH1A1HSD17B10ACP3CYP2C19 | |
| SCHEMBL29081148 | 0.80 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10ACP3NR4A1 | |
| SCHEMBL29608063 | 0.80 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10ACP3NR4A1 | |
| SCHEMBL146376 | 0.80 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10ACP3NR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021054927-A2 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | SOUTH DAKOTA BOARD OF REGENTS (US) | 2021-03-25 | — | — | WO | claimed |
| US-20200048305-A1 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | SOUTH DAKOTA BOARD OF REGENTS (US) | 2020-02-13 | — | — | US | claimed |
| US-9622969-B2 | Polymer conjugated protein micelles | SOUTH DAKOTA STATE UNIV (US) | 2017-04-18 | — | — | US | claimed |
| US-20140370110-A1 | POLYMER CONJUGATED PROTEIN MICELLES | SOUTH DAKOTA STATE UNIVERSITY (US) | 2014-12-18 | — | — | US | claimed |
| US-7728096-B2 | Adhesive having aromatic diisocyanates and aromatic petroleum distillates with low volatility for use in engineered wood products | WEYERHAEUSER NR COMPANY (US) | 2010-06-01 | — | — | US | claimed |
| US-20080135173-A1 | Adhesive Having Aromatic Diisocyanates And Aromatic Petroleum Distillates With Low Volatility For Use In Engineered Wood Products | WEYERHAEUSER CO. (US) | 2008-06-12 | — | — | US | claimed |
| EP-1429807-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA Pharma AG (DE) | 2004-06-23 | — | — | EP | claimed |
| WO-2003024489-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | claimed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| CN-117597327-A | Pharmaceutical preparation | 第一波动生物制药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2023118074-A1 | COMPRESSIBLE AND FREE FLOWING CO-PROCESSED MESOPOROUS SILICA | UNIVERZA V LJUBLJANI (SI) | 2023-06-29 | — | — | WO | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| EP-0283796-A1 | Device for converting electrolytic cells of filter press type into cells with continuously renewable sacrificial electrodes | Silvestri, Giuseppe (IT) | 1988-09-28 | — | — | EP | disclosed |
| EP-0072884-B1 | PROCESS FOR PRODUCTION OF ALPHA-HALOALKYLAMIDES | STAUFFER CHEMICAL COMPANY (US) | 1986-08-20 | — | — | EP | disclosed |
| EP-0072884-A2 | Process for production of alpha-haloalkylamides | STAUFFER CHEMICAL COMPANY (US) | 1983-03-02 | — | — | EP | disclosed |
| US-4358612-A | Process for production of α-haloalkylamides | STAUFFER CHEMICAL COMPANY (US) | 1982-11-09 | — | — | US | disclosed |
| US-3998880-A | Production of N,N-diethyl 2(α-naphthoxy)propionamide | STAUFFER CHEMICAL COMPANY (US) | 1976-12-21 | — | — | US | disclosed |
| US-3956209-A | POLYSILOXANES, ALKYL SILICATES, FILLERS | GENERAL ELECTRIC COMPANY (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | KDM4E 2452/4885ALDH1A1 2174/4885HSD17B10 528/4885 |
| US-20200048305-A1 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | GSTK1, GSTO1, GSTM2 | KDM4E 4520/4885ALDH1A1 2491/4885HSD17B10 492/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | KDM4E 3249/4885ALDH1A1 3977/4885HSD17B10 2468/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | KDM4E 3157/4885ALDH1A1 3889/4885HSD17B10 2422/4885 |
| US-20140370110-A1 | POLYMER CONJUGATED PROTEIN MICELLES | MTDH, PSMG3, GHITM | KDM4E 3234/4885ALDH1A1 4150/4885HSD17B10 3318/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | KDM4E 2466/4885ALDH1A1 2230/4885HSD17B10 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.